tirzepatide provider Injection | Starts at $249/mo Oral tirzepatide for flexible weight-loss

BYETTA was studied in 282 patients 65 years of age or older and in 16 patients 75 years of age or older

no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects

Complex carbohydrates like grains, beans, fruits, and vegetables give you instant energy, let you store energy, aid in any digestive issues from GLP1 meds such as constipation, and help you feel full

Avexitide (Exendin (9-39)), a truncated form of the GLP-1 agonist exendin-4, is a specific GLP-1 receptor antagonist [1]